Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Bokf Na

Bokf Na trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 5.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,717 shares of the company’s stock after selling 853 shares during the period. Bokf Na’s holdings in Moderna were worth $1,866,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the 2nd quarter valued at about $26,000. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Moderna in the fourth quarter valued at approximately $27,000. Family Firm Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $33,000. Cedar Wealth Management LLC increased its holdings in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Finally, Westside Investment Management Inc. purchased a new position in Moderna during the first quarter worth approximately $32,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRNA. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Jefferies Financial Group downgraded shares of Moderna from a “buy” rating to a “hold” rating and reduced their target price for the stock from $120.00 to $65.00 in a research note on Friday. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. TD Cowen cut their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday. Finally, Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $108.53.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. Insiders have sold a total of 108,158 shares of company stock worth $13,239,712 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Moderna Price Performance

Moderna stock opened at $68.28 on Friday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The firm has a market cap of $26.17 billion, a PE ratio of -4.36 and a beta of 1.67. The company’s 50 day moving average is $95.06 and its two-hundred day moving average is $111.79.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.62) EPS. On average, research analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.